Galmed Pharmaceutica (GLMD) Stock Price, Quote & News

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 693 8448

Fax: 972 3 693 8447

Website: galmedpharma.com

Address:

16 Abba Hillel Road, Ramat Gan, Israel

AYRO_best_short_ever Aug. 26 at 10:07 PM

$GLMD just follow pumpnation1, just dont buy when he pumps..

0 · Reply

madan_shatri Aug. 26 at 9:38 PM

$GLMD come onnnnnn. dont let us wait for months. Hit the double digits

0 · Reply

VolcanicTrades Aug. 26 at 8:26 PM

$GLMD the reality is that this one is going to sting the bears if they don’t clear out soon 👍🏻

1 · Reply

Morpomex Aug. 26 at 7:27 PM

$GLMD

0 · Reply

BULLNATION1 Aug. 26 at 5:46 PM

$GLMD ALERT 🚨 INVERTED RSI DIVERGENCE = RSI divergences occur when the price of an asset moves in one direction while the Relative Strength Index (RSI) moves in the opposite direction. This indicates a mismatch between price action and momentum, often hinting at a trend reversal or pause. Great loading up opportunity, invest or plan it yourself!

0 · Reply

Shakattack31 Aug. 26 at 5:39 PM

$GLMD so whats you're guess the up coming catalyst ?

0 · Reply

CalculatedSwing Aug. 26 at 5:32 PM

$SERA always early $GLMD

0 · Reply

boomshiva Aug. 26 at 5:17 PM

$GLMD Don't know what mgmt was hoping for with yesterday's announcement. Using current cash to buy crypto doesn't change the pharma development business. Having 900 Mill AS is great, but you have to sell shares to buy crypto, and that registration statement is going to drag SP closer to $1.00 (unless they use the SEPA with YA II to sell them what's left under the SEPA). Whatever they have up their sleeve, I hope it's a good one and soon.

0 · Reply

lookgoodplaygood22 Aug. 26 at 3:41 PM

$GLMD they do not want this going below this level. That is apparent.

1 · Reply

Morpomex Aug. 26 at 3:40 PM

$GLMD I hope in the next week or 2 to get some sort of good news.

0 · Reply

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

May 27, 2025, 8:00 AM EDT - 3 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 22, 2025, 8:00 AM EDT - 3 months ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 4 months ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 17, 2025, 8:30 AM EDT - 4 months ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 15, 2025, 8:30 AM EDT - 4 months ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 4 months ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 2, 2025, 4:10 PM EDT - 5 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 20, 2025, 8:55 AM EDT - 5 months ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Sep 25, 2024, 8:00 AM EDT - 11 months ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Apr 4, 2024, 5:06 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Mar 15, 2024, 9:00 AM EDT - 1 year ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Nov 20, 2023, 4:32 PM EST - 1 year ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 22, 2023, 4:05 PM EDT - 2 years ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 14, 2023, 9:30 AM EDT - 2 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

May 9, 2023, 7:00 AM EDT - 2 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Mar 29, 2023, 5:00 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Feb 8, 2023, 8:00 AM EST - 2 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Dec 14, 2022, 5:00 PM EST - 2 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Jul 7, 2022, 8:27 AM EDT - 3 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

May 17, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 7:30 AM EDT - 3 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 2, 2022, 1:56 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

May 2, 2022, 7:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Apr 28, 2022, 7:00 AM EDT - 3 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Jan 11, 2022, 7:30 AM EST - 3 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 10, 2022, 9:14 AM EST - 3 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 7:30 AM EST - 3 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Nov 8, 2021, 3:24 PM EST - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 7:30 AM EST - 4 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:00 AM EST - 4 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 1, 2021, 10:10 AM EDT - 4 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Oct 11, 2021, 8:00 AM EDT - 4 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

Aug 16, 2021, 8:00 AM EDT - 4 years ago

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Aug 9, 2021, 11:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript

Aug 5, 2021, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Aug 2, 2021, 9:26 AM EDT - 4 years ago

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial

Aug 2, 2021, 7:30 AM EDT - 4 years ago

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

Jul 29, 2021, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5

May 13, 2021, 6:58 PM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript

May 13, 2021, 7:50 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results

AYRO_best_short_ever Aug. 26 at 10:07 PM

$GLMD just follow pumpnation1, just dont buy when he pumps..

0 · Reply

madan_shatri Aug. 26 at 9:38 PM

$GLMD come onnnnnn. dont let us wait for months. Hit the double digits

0 · Reply

VolcanicTrades Aug. 26 at 8:26 PM

$GLMD the reality is that this one is going to sting the bears if they don’t clear out soon 👍🏻

1 · Reply

Morpomex Aug. 26 at 7:27 PM

$GLMD

0 · Reply

BULLNATION1 Aug. 26 at 5:46 PM

0 · Reply

Shakattack31 Aug. 26 at 5:39 PM

$GLMD so whats you're guess the up coming catalyst ?

0 · Reply

CalculatedSwing Aug. 26 at 5:32 PM

$SERA always early $GLMD

0 · Reply

boomshiva Aug. 26 at 5:17 PM

0 · Reply

lookgoodplaygood22 Aug. 26 at 3:41 PM

$GLMD they do not want this going below this level. That is apparent.

1 · Reply

Morpomex Aug. 26 at 3:40 PM

$GLMD I hope in the next week or 2 to get some sort of good news.

0 · Reply

whippster Aug. 26 at 3:01 PM

$GLMD getting bored but still holding tight for now

0 · Reply

CalculatedSwing Aug. 26 at 2:35 PM

$AXTI will be 7.00 eoy... was right about $ONDS and I'm right about this. 200k position. Not selling now.. despite being up a metric tonne $GLMD $MBOT $MVIS

1 · Reply

VolcanicTrades Aug. 26 at 2:31 PM

$GLMD

0 · Reply

AYRO_best_short_ever Aug. 26 at 2:27 PM

$GLMD @BULLNATION1 is pumpnation still pumping this? 🥴

1 · Reply

TG1019 Aug. 26 at 2:24 PM

$GLMD LFGGGG gimme 1.83 so I can get out of this nightmare

1 · Reply

BiotechValues Aug. 26 at 1:14 PM

$GLMD did they abandon the in-license? Or no one knows?

1 · Reply

Nickyboy1234 Aug. 26 at 12:28 PM

$GLMD earnings today and will show that we are cash heavy

1 · Reply

VolcanicTrades Aug. 26 at 12:00 PM

$GLMD

0 · Reply

CalculatedSwing Aug. 26 at 11:56 AM

$GLMD $GLMD Eyes on the horizon! With $15.7M cash & no debt, Galmed’s pivoting smart—$10M into digital assets could be a game-changer. ARMOR study’s open-label success (anti-fibrotic wins in 2022/24) hints at a 2026 approval shot, even with the double-blind pause. Termination of the Entomus deal opens new doors—minority stake move might spark partnerships. Down 27% this month, but low float & NASH potential could fuel a rebound. Watch for Q3 updates! #biotech #NASH #investing $VOR

0 · Reply

Morpomex Aug. 26 at 11:51 AM

$GLMD

0 · Reply

elmono Aug. 26 at 7:05 AM

$GLMD Bullnation1 being a delusional little pump tart that has zero creds. Still wet behind the ears …will not end well 😂😂😂

1 · Reply

funnymoney90210 Aug. 26 at 3:50 AM

$GLMD This should be $13 by now

1 · Reply

Market Cap	2.47M
Revenue (ttm)	0.00
Net Income (ttm)	-7.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	101,800
Avg Vol	326,094
Day's Range	N/A - N/A
Shares Out	1.65M
Stochastic %K	20%
Beta	0.58
Analysts	Hold
Price Target	$12.00